Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GsMTx4 is a **peptide toxin** originally found in the venom of the tarantula Grammostola spatulata. It is a member of the inhibitory cysteine knot (ICK) peptide family and is a gating modifier of mechanosensitive ion channels, with a unique structural motif enabling high potency for inhibiting mechanosensitive cation channels. GsMTx4 inhibits a range of mechanosensitive cationic channels, including Piezo1, Piezo2, and members of the TRP channel family (such as TRPC1 and TRPC6). Unlike most drugs, its inhibition is not stereospecific—both L- and D- forms are active, suggesting a membrane-mediated mechanism of action. It has demonstrated protective effects in preclinical models of muscular dystrophy and cardiac arrhythmias, and shows promise in conditions such as Duchenne muscular dystrophy, atrial fibrillation, mechanical pain, and possibly neurodegenerative diseases and osteoarthritis. GsMTx4 is not currently approved for human therapeutic use but is being developed as an investigational agent and research tool[1][3][4][5][6][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GsMTx4.